Tag

Neurodegenerative Disease

All articles tagged with #neurodegenerative disease

Quadruple Risk: Study Links NFL Careers to Higher Neurodegenerative Deaths
health6 days ago

Quadruple Risk: Study Links NFL Careers to Higher Neurodegenerative Deaths

A Mass General Brigham–Boston University–CTE Foundation study of nearly 20,000 NFL players finds death from neurodegenerative disease is about four times higher than in the general population, with dementia and Parkinson’s deaths 3–4x more common; longer careers (five-plus seasons) nearly double the risk versus shorter careers. CTE is considered the primary explanation, though players generally live longer overall due to other protective factors.

Hidden Brain Drain Path Discovered Along the Dura Near a Key Artery
science5 months ago

Hidden Brain Drain Path Discovered Along the Dura Near a Key Artery

Researchers identified a slow, lymphatic-like drainage channel in the dura surrounding the middle meningeal artery in healthy adults, using dynamic MRI and postmortem tissue with lymphatic markers PROX1, PDPN, LYVE1. This pathway could help clear cerebrospinal and interstitial fluids, reshaping how we understand brain waste clearance and potentially impacting aging and diseases like Alzheimer’s, while reinforcing the dura as an active immune interface rather than a static barrier.

Psychiatric Medications Associated with Increased ALS Risk and Progression
health1 year ago

Psychiatric Medications Associated with Increased ALS Risk and Progression

A Swedish study found that the use of psychiatric medications such as anxiolytics, hypnotics, sedatives, and antidepressants is associated with an increased risk of developing ALS and worse outcomes after diagnosis, including shorter survival and faster functional decline, suggesting a potential link between psychiatric symptoms, medications, and ALS progression.

QurAlis Begins Phase 1 Trial of QRL-101 for ALS Treatment
health1 year ago

QurAlis Begins Phase 1 Trial of QRL-101 for ALS Treatment

Quralis has initiated a Phase 1 clinical trial for QRL-101, a novel treatment aimed at reducing nerve cell overactivation in amyotrophic lateral sclerosis (ALS) patients, potentially slowing disease progression. The trial, conducted in the Netherlands, will assess the safety, tolerability, and pharmacological properties of QRL-101. This first-in-class therapy targets Kv7.2/7.3 ion channels to control motor neuron hyperexcitability, a key factor in ALS progression. Results from this study, along with parallel research, will guide future development of QRL-101.

"Plexin-B1 Protein: A New Target in Alzheimer's Treatment"
health-and-science2 years ago

"Plexin-B1 Protein: A New Target in Alzheimer's Treatment"

Researchers at Mount Sinai Hospital have discovered that targeting the plexin-B1 protein can enhance the brain's ability to clear amyloid plaques, potentially slowing or halting Alzheimer's progression. This breakthrough emphasizes the role of reactive astrocytes and cellular interactions in developing new treatments for Alzheimer's disease.

"Early Detection and Life-Changing Treatments: The Latest Breakthroughs in Alzheimer's Research"
health2 years ago

"Early Detection and Life-Changing Treatments: The Latest Breakthroughs in Alzheimer's Research"

The AHEAD study aims to identify risk factors for Alzheimer's, such as the buildup of amyloid proteins, in healthy individuals 15-20 years before symptom onset, offering them the opportunity to participate in a new FDA-approved medication trial designed to prevent or lessen the effects of the disease. The study, conducted at 75 sites nationwide, is open to all populations and aims to provide free monitoring and access to care, particularly for minority groups who may face disparities in healthcare access.

"Manufacturer Withdraws ALS Drug from Market After Failed Clinical Trial"
health2 years ago

"Manufacturer Withdraws ALS Drug from Market After Failed Clinical Trial"

Amylyx, the maker of the ALS drug Relyvrio, is pulling the drug from the market and laying off 70% of its workforce after a large clinical trial showed the drug did not help patients. The drug, approved by the FDA in September 2022, failed to meet its goals in a 48-week trial involving 664 patients, leading to its withdrawal from the market. Patients already taking the medication can continue through a free drug program, but it is no longer available to new patients. Amylyx is now focusing on other drug candidates for neurodegenerative diseases and will lay off most of its employees.